Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been found to play a key role in the pathogenesis of MDS. There is a growing interest, by researchers, as well as clinicians, to better understand the role of the innate immune system in this disease, and further investigate novel agents and strategies to treat patients at an earlier stage.
In this podcast, you will hear from leading experts Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL, who discuss the role of the innate immune system in MDS, and further highlight the role of chronic inflammation in this disease, as well as future therapeutic strategies.
The post The role of the innate immune system in MDS appeared first on VJHemOnc.
